Challenger Limited (ASX:CGF) has disclosed that its Board has concluded a non-binding indicative offer from TAL Daiichi Life Australia Pty Limited (TDA) to acquire the remaining ordinary shares in Challenger by way of a scheme of arrangement at $11.80 per share is not at a level it could recommend to shareholders.
Key Points
- TDA made a non-binding, conditional indicative offer to acquire the remaining ordinary shares in Challenger it does not already own at $11.80 per share via a scheme of arrangement, as announced on 19 October 2026.
- The Challenger Board met and carefully considered the offer, having regard to Challenger's value and prospects, and concluded the offer is not at a level it could recommend to shareholders.
- The Board intends to engage with TDA to determine whether a proposal can be reached that the Board could recommend.
- There is no certainty the proposal will result in a binding offer or that any transaction will eventuate.
Board Response to TDA's Indicative Offer
Challenger's Board met and carefully considered TDA's non-binding and conditional indicative offer to acquire the remaining ordinary shares in Challenger that TDA does not already own, at a price of $11.80 per share by way of a scheme of arrangement. According to the filing dated 26 October 2026, the Board concluded the offer is not at a level it could recommend to shareholders. The Board's assessment was made having regard to Challenger's value and prospects, as disclosed in the company update.
Planned Engagement with TDA
Despite rejecting the offer at its current level, the Challenger Board stated it highly values TDA as its largest shareholder and a commercial partner. The filing states that the Board intends to engage with TDA to see whether a proposal can be reached that the Board could recommend to shareholders. The company has made clear there is no certainty that the proposal will result in a binding offer, or that any transaction will eventuate. Challenger shareholders have been advised they do not need to take any action at this time.
Background to the Indicative Offer
The filing refers to Challenger's earlier disclosure dated 19 October 2026, in which the non-binding and conditional indicative offer from TAL Daiichi Life Australia Pty Limited was first announced. TDA's proposed transaction structure was a scheme of arrangement covering the ordinary shares in Challenger not already held by TDA. The 26 October 2026 release was authorised by Challenger's Continuous Disclosure Committee. Challenger is described in the filing as an APRA-regulated life company listed on the Australian Securities Exchange, with a purpose of providing customers with financial security for retirement.





Please wait processing your request...